SAB Biotherapeutics (SABS) EBIT Margin (2021 - 2024)
SAB Biotherapeutics (SABS) posted EBIT Margin of -8726.26% for Q4 2024, down 2538.36 percentage points from -6187.90% a year earlier.
Powered by 
Analysis
SAB Biotherapeutics (SABS) EBIT Margin (2021 - 2024) Analysis & Trends
For FY2024, SAB Biotherapeutics' EBIT Margin came in at -3244.87%, down 1544.32 percentage points from FY2023.
- Annual EBIT Margin has declined for four consecutive years, with a four-year change of -3282.09 percentage points (FY2020 to FY2024).
- In prior years, SAB Biotherapeutics' EBIT Margin was -1700.56% in FY2023 (-1579.58 pp), -120.97% in FY2022 (-98.97 pp), -22.00% in FY2021 (-59.22 pp) and 37.22% in FY2020.
- The Q4 2024 figure stands as the lowest quarterly EBIT Margin in data going back to Q1 2021.
- On a year-over-year basis, EBIT Margin increased in two of the last seven quarters, with an average year-over-year change of -1926.86 percentage points.
- The strongest year-over-year quarter for EBIT Margin in the past five years was Q2 2024, with a gain of 3696.44 percentage points; the weakest was Q2 2023, with a drop of 7470.37 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | SAB Biotherapeutics | 268.01 Mn | 268.01 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -8,726.26% |
| Jun 30, 2024 | -3,876.95% |
| Mar 31, 2024 | -1,205.90% |
| Dec 31, 2023 | -6,187.90% |
| Sep 30, 2023 | -420.00% |
| Jun 30, 2023 | -7,573.40% |
| Mar 31, 2023 | -1,273.79% |
| Dec 31, 2022 | -363.74% |
| Sep 30, 2022 | -217.49% |
| Jun 30, 2022 | -103.03% |
| Mar 31, 2022 | -56.83% |
| Dec 31, 2021 | -66.41% |
| Sep 30, 2021 | -27.18% |
| Jun 30, 2021 | -15.77% |
| Mar 31, 2021 | 4.81% |
API Access
SAB Biotherapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();